Is Bosulif being withdrawn (pulled from the market)?
Yes. Bosulif (bosutinib) has been withdrawn in some countries and is no longer available in certain markets, typically after regulators and/or the manufacturer determined it was no longer appropriate to continue marketing. Availability depends on the country and the time period.
Why would a drug like Bosulif be withdrawn?
Common reasons regulators withdraw oncology products include:
- Safety or tolerability concerns that emerge after broader use
- Changes in the product’s risk-benefit balance
- Company decisions to discontinue supply in a region
- Patent exclusivity or commercial strategy shifts that affect continued marketing (rather than approval)
Is it withdrawn everywhere or only in certain places?
Withdrawal is usually not global. You can see different statuses by country (e.g., “discontinued,” “suspended,” or “withdrawn”) and by the specific strength/formulation.
If you tell me your country (or the country where your pharmacy says it’s unavailable), I can help narrow down whether it was withdrawn there and when.
What should patients do if Bosulif is no longer available?
If your prescriber says Bosulif is unavailable, next steps usually involve switching to an alternative therapy for CML/Ph+ disease under an oncologist’s guidance (and adjusting based on prior treatment history and response). Do not stop without a plan, because treatment interruptions can affect disease control.
Where can you check withdrawal/discontinuation status?
For patent and regulatory context (including manufacturer and market exclusivity information), DrugPatentWatch.com is one useful reference point: https://www.drugpatentwatch.com/